SCHEMBL3848644

SCHEMBL3848644

CCOC(=O)c1c(O)c(C)nn(Cc2ccccc2)c1=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.67
ALDH1A1 P00352 4/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
LMNA P02545 2/20 0.54
HPGD P15428 1/20 0.54
POLB P06746 2/20 0.53
KDM4E B2RXH2 3/20 0.52
PDE4D Q08499 3/20 0.52
PDE4A P27815 2/20 0.52
PDE4B Q07343 2/20 0.52
PDE4C Q08493 2/20 0.52
CYP19A1 P11511 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
RECQL P46063 1/20 0.50
MAPT P10636 1/20 0.49
HTT P42858 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
HSD17B10 Q99714 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3851363 0.88 PDE4A (0.61) MAPK1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL3853119 0.87 MAPK1 (0.55) MAPK1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL3851359 0.86 MAPK1 (0.54) MAPK1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL14088339 0.84 MAPK1 (0.52) MAPK1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL6070204 0.83 MAPK1 (0.76) MAPK1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL3854700 0.82 MAPK1 (0.50) MAPK1ALDH1A1SMN1; SMN2POLBKDM4E
SCHEMBL3849121 0.81 MAPK1 (0.48) MAPK1ALDH1A1SMN1; SMN2LMNAHPGD
SCHEMBL3849282 0.81 MAPK1 (0.48) MAPK1ALDH1A1SMN1; SMN2LMNAHPGD
SCHEMBL20551943 0.81 MAPK1 (1.00) MAPK1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL3847510 0.80 EGLN3 (0.55) MAPK1ALDH1A1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2889289-A1 Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors GlaxoSmithKline LLC (US) 2015-07-01 EP disclosed
US-RE44613-E1 N-substituted glycine derivatives: hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2013-11-26 US disclosed
CN-101626685-B N-substituted glycine derivatives: hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2013-03-13 CN disclosed
CN-101626685-A The glycine derivative that N-replaces: hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2010-01-13 CN disclosed
US-7608621-B2 Such as n-{[2-[(4-bromo-2-fluorophenyl)methyl]-5-hydroxy-6-(1-methylethyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine; anemia; increasing erythropoietin production SMITHKLINE BEECHAM, CORP. (US) 2009-10-27 US disclosed
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors GLAXOSMITHKLINE LLC 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors EGLN2, EGLN3, HIF1AN MAPK1 2489/4885ALDH1A1 564/4885SMN1; SMN2 3490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.